Your browser doesn't support javascript.
loading
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
Pernigoni, Nicolò; Zagato, Elena; Calcinotto, Arianna; Troiani, Martina; Mestre, Ricardo Pereira; Calì, Bianca; Attanasio, Giuseppe; Troisi, Jacopo; Minini, Mirko; Mosole, Simone; Revandkar, Ajinkya; Pasquini, Emiliano; Elia, Angela Rita; Bossi, Daniela; Rinaldi, Andrea; Rescigno, Pasquale; Flohr, Penny; Hunt, Joanne; Neeb, Antje; Buroni, Lorenzo; Guo, Christina; Welti, Jonathan; Ferrari, Matteo; Grioni, Matteo; Gauthier, Josée; Gharaibeh, Raad Z; Palmisano, Anna; Lucchini, Gladys Martinetti; D'Antonio, Eugenia; Merler, Sara; Bolis, Marco; Grassi, Fabio; Esposito, Antonio; Bellone, Matteo; Briganti, Alberto; Rescigno, Maria; Theurillat, Jean-Philippe; Jobin, Christian; Gillessen, Silke; de Bono, Johann; Alimonti, Andrea.
Affiliation
  • Pernigoni N; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Zagato E; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Calcinotto A; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Troiani M; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Mestre RP; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Calì B; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Attanasio G; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Troisi J; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Minini M; Medical Oncology Unit, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
  • Mosole S; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Revandkar A; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Pasquini E; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Elia AR; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Bossi D; Theoreo Srl, Montecorvino Pugliano, 84090 Salerno, Italy.
  • Rinaldi A; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Rescigno P; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Flohr P; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Hunt J; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Neeb A; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Buroni L; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Guo C; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Welti J; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Ferrari M; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Grioni M; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Gauthier J; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Gharaibeh RZ; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • Palmisano A; Institute of Oncology Research, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
  • Lucchini GM; Faculty of Biomedical Sciences, Università della Svizzera Italiana, CH-1011 Lugano, Switzerland.
  • D'Antonio E; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060 Turin, Italy.
  • Merler S; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Bolis M; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Grassi F; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Esposito A; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Bellone M; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Briganti A; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
  • Rescigno M; Medical Oncology Unit, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
  • Theurillat JP; Cellular Immunology Unit, IRCCS Ospedale San Raffaele, 20100 Milan, Italy.
  • Jobin C; Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Florida College of Medicine, Gainesville, FL, USA.
  • Gillessen S; Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Florida College of Medicine, Gainesville, FL, USA.
  • de Bono J; Experimental Imaging Center, San Raffaele Scientific Institute, 20100 Milan, Italy.
  • Alimonti A; School of Medicine, University Vita-Salute San Raffaele, Milan, Italy.
Science ; 374(6564): 216-224, 2021 Oct 08.
Article in En | MEDLINE | ID: mdl-34618582
ABSTRACT
The microbiota comprises the microorganisms that live in close contact with the host, with mutual benefit for both counterparts. The contribution of the gut microbiota to the emergence of castration-resistant prostate cancer (CRPC) has not yet been addressed. We found that androgen deprivation in mice and humans promotes the expansion of defined commensal microbiota that contributes to the onset of castration resistance in mice. Specifically, the intestinal microbial community in mice and patients with CRPC was enriched for species capable of converting androgen precursors into active androgens. Ablation of the gut microbiota by antibiotic therapy delayed the emergence of castration resistance even in immunodeficient mice. Fecal microbiota transplantation (FMT) from CRPC mice and patients rendered mice harboring prostate cancer resistant to castration. In contrast, tumor growth was controlled by FMT from hormone-sensitive prostate cancer patients and Prevotella stercorea administration. These results reveal that the commensal gut microbiota contributes to endocrine resistance in CRPC by providing an alternative source of androgens.
Subject(s)

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Bacteria / Prostatic Neoplasms, Castration-Resistant / Gastrointestinal Microbiome / Host Microbial Interactions / Androgens Limits: Aged / Aged80 / Animals / Humans / Male / Middle aged Language: En Journal: Science Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Bacteria / Prostatic Neoplasms, Castration-Resistant / Gastrointestinal Microbiome / Host Microbial Interactions / Androgens Limits: Aged / Aged80 / Animals / Humans / Male / Middle aged Language: En Journal: Science Year: 2021 Document type: Article